Abstract
DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to those of moxifloxacin yet is more active than moxifloxacin during both the initial and continuation phases of treatment in a murine model. These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminopyridines / blood
-
Aminopyridines / pharmacokinetics
-
Aminopyridines / therapeutic use*
-
Animals
-
Antitubercular Agents / blood
-
Antitubercular Agents / pharmacokinetics
-
Antitubercular Agents / therapeutic use*
-
Female
-
Fluoroquinolones / blood
-
Fluoroquinolones / pharmacokinetics
-
Fluoroquinolones / therapeutic use*
-
Mice
-
Mice, Inbred BALB C
-
Tuberculosis / drug therapy*
Substances
-
7-(7-amino-7-methyl-5-azaspiro(2.4)heptan-5-yl)-6-fluoro-1-(2-fluoro-1-cyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
-
Aminopyridines
-
Antitubercular Agents
-
Fluoroquinolones